SEC Form D private-offering filing

CASI Pharmaceuticals, Inc.

Name: CASI Pharmaceuticals, Inc. - new SEC Form D private-offering filing, Beijing
Published: 2026-02-26

A new SEC Form D private-offering notice from Beijing, a $5,000,000 filer-stated offering target in Biotech. The source filing is one click away.

CASI Pharmaceuticals, Inc. site↗ Verified via SEC Form D

Nasdaq listed biopharmaceutical company developing therapeutics including an anti CD38 antibody for transplant rejection, with China operations run through a Beijing subsidiary

Filed 2026-02-26Filed to raise $5,000,000First money in 2026-02-19Raised so far $5,000,000HQ (as filed) BeijingSector Biotech ✓Stage (inferred) EarlyCall status Needs classification

Source linked the Form D on EDGAR↗Website verified casipharmaceuticals.com↗Named in the filing 14 executives & directors

Open this row on the live feed →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.